CVS — Stock Film
STOCK FILMSCENE 1/11CVS · $93.65
Stock Expert AI presents
CVS
CVS Health Corp
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
CVS Health Corp. A quick introduction.

On the stock market since 1973, it operates in the world of health and science. It has 300,000 employees. Now — the numbers.

on the stock market since 1973
300K employees
$137B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, less than $1 stays as net profit.

This is an established company with proven profits.

THE SALES TREND
Sales are growing, year after year.

Average growth of 8% a year over the last 4 years. Every year shown ended in profit.

$292B
2021
$322B
2022
$358B
2023
$373B
2024
$402B
2025
Cash on hand:
$0
Total debt:
$0
The debt outweighs the cash.

The gap is $82.9B. In times of high interest rates, a gap like that can squeeze a company.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
74
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
31
very weak

Clearly below the class average.

VALUATION
92
very strong

The price looks reasonable next to what the company earns.

GROWTH
49
weak

Clearly below the class average.

PRICE MOMENTUM
58
average

The price is looking for direction — no strong breakout, no collapse.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Few are betting against it10/10
WEAK SPOTS
Thin profit on each sale3/10
Costs eat into the margin4/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 16% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

2
THE BRIGHT SIDE · 2/3
Executives are buying their own stock

Over the last 12 months, company executives reported 42 buys and 30 sells. Management buying with its own money is usually read as a good sign.

3
THE BRIGHT SIDE · 3/3
Analysts’ target sits above today’s price

The average analyst price target is $11018% above today’s price.

1
THE RISKS · 1/3
A rich price tag

The company’s market value is 78 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 31/100.

3
THE RISKS · 3/3
Growth trails the sector

The growth engine is running at low revs right now. Report-card grade: 49/100.

FINALE · THE GRADE
B
0 / 100 · MoonshotScore

On our five-subject report card, CVS sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: CVS is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film